Epilepsy News

Patients with Lennox-Gastaut syndrome experienced a significant reduction in drop seizures with fenfluramine, according to results of a clinical trial published in JAMA Neurology.

Boston Scientific Corp. announced it has received FDA approval for its image-guided software for deep brain stimulation therapy in patients with Parkinson’s disease.

SEATTLE — Subtypes of seizures have improved through the use of cenobamate, William E. Rosenfeld, MD, FAAN, said at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Higher frequency of seizures and relatively poor quality of life are significant risk factors for depression in patients with epilepsy, according to a presentation at the 2022 American Academy of Neurology annual meeting.

The presence of newborn neurons and an immature version of a related cell, known as astroglia, were found in patients with epilepsy, researchers reported in Nature Neuroscience.

SEATTLE — Sarah J. Spence, MD, PhD, shared tips on differentiating pediatric neurological conditions with overlapping symptoms, at the 2022 American Academy of Neurology annual meeting.

Natalia S. Rost, MD, MPH, chair of the AAN science committee, led a discussion to highlight select studies being presented at the AAN’s annual meeting April 2-7 in Seattle.

Pharmaceutical company Lupin announced that the FDA has approved its abbreviated new drug application for anti-epileptic vigabatrin for oral solution, according to a press release.

Intensive anti-seizure treatment suppressing rhythmic and periodic electroencephalographic patterns in comatose survivors of cardiac arrest did not result in fewer poor outcomes at 3 months vs. standard treatment, researchers reported.

Medical device company Precisis GmbH announced its EASEE brain stimulator has received breakthrough device designation from the FDA, according to a press release.